ANVS - Annovis Bio 23:20 PM - Jul 29 2021
by: Maverick

ANVS - Data Release - July 28, 2021

Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference -

ANVS - Annovis Bio 22:10 PM - Jul 22 2021
by: Maverick

ANVS - Updates on Phase 2a Trials (AD) at AAIC 2021

Annovis Bio's lead drug candidate, ANVS401, will be featured in a poster presentation: Positive Clinical Outcomes in Two Phase 2a Studies: ADAS-Cog in Alzheimer's and MDS-UPDRS in Parkinson's patients plus Markers of Toxic Cascade that Leads to Nerve Cell Death.

Previously, Annovis Bio reported that AD patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11); PD patients treated with ANVS401 showed statistically significant motor function improvement as measure by the MDS-UPDRS. Additionally, in a test that measures speed and accuracy, AD and PD patients both responded with a statistically significant increase in correctly coded fields. The company also measured inflammatory factors and found statistically significant lowering of these factors. These tests were part of the Company's ongoing Phase 2a study in AD and PD patients.

ANVS - Annovis Bio 01:27 AM - Jun 13 2021
by: Maverick

ANVS - Annovis Bio - DD - June 2021

  • Current Price (June 13): 91.00 (found at 47)
  • O/S 7M
  • Float 4.7M
  • Cash ~50M
  • Market cap: ~$700M


Our Pipeline consists of drugs for chronic neurodegeneration - Alzheimer’s disease (AD), its orphan indication Alzheimer’s disease and dementia in Down syndrome (AD-DS) and Parkinson’s disease (PD). Additionally, we have a compound to treat acute neurodegeneration - traumatic brain injury (TBI) and stroke - and a third compound for advanced AD.

We Are Working to REVERSE the Toxic Cascade

Recent updates

June 2021 Investor Presentation (must read) -

Upcoming catalysts
  • Phase 2 full data July / August 2021 for ANVS401  -- Alzheimer’s disease (AD) and Parkinson’s disease (PD) - they haven't said a date yet, but I'm guessing it'll be at the AAIC on July 26-30 -- (they are a platinum sponsor...)

Heads up
As always, there's two major warnings with any biotech: data could turn out bad (despite expectations otherwise) and offerings are ever looming (since most biotechs have no revenue).  I wouldn't be surprised to see an offering in late June/early July if this price stays up here.

My notes
  • They recently did an offering of 1M shares @ 50, putting $50M in the coffers
  • As you can see from the trades on this board, I ran into this around 47.  It. moves. fast.  I currently have no position (have bought and sold several times), but I'll be back in by end of June ahead of data release in July
  • I really like this one.  I can't find any reason to dislike it, even at 90.

Annovis Bio - ANVS

Total Followers: 1
Latest ANVS News

Link Copied to Clipboard!